Adjust Font Increase Font Decrease Font
  • Email
  • Print
  • RSS Feed

Media Releases

PhRMA Statement on India Supreme Court Decision on Glivec
WASHINGTON, D.C. (April 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today: “PhRMA is very disappointed with the Indian Supreme Court’s decision to deny a patent on Glivec. This decision marks yet another example of the deteriorating innovation environment in India.  Innovation is critical in meeting unmet needs of patients and is particularly relevant in the context of changing healthcare systems. In order to solve the real health challenges of India’s patients, it is critically important that India promote a policy environment that supports continued research and development of new medicines for the health of patients in India and worldwide. Protecting intellectual...
Read more

Latest Releases

PhRMA Statement on India Supreme Court Decision on Glivec
4/1/2013
WASHINGTON, D.C. (April 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today: “PhRMA is very disappointed with the Indian Supreme Court’s decision to deny a patent on Glivec. This decision marks yet another example of the deteriorating innovation environment in India. Innovation is critical in meeting unmet needs of patients and is particularly relevant in the context of changing healthcare systems."
More
Rx Response Director Erin Mullen Receives Outstanding Achievement Award at National Hurricane Conference
3/28/2013
New Orleans, LA (March 27, 2013) – Rx Response Director and PhRMA Associate Vice President for IT & Operations Erin Mullen, PhD., RPh, CEM, received the Outstanding Achievement Award for Preparedness at the National Hurricane Conference in New Orleans today.
More
Over 8,200 Clinical Trials of Medicines Conducted by Texas Research Institutions Since 1999
3/25/2013
Research Supported by Biopharmaceutical Companies is Boost to Texas Economy
WASHINGTON, D.C. (March 25, 2013) – Working incollaboration with university medical schools and science centers, local hospitals and clinical research facilities, America’s biopharmaceutical companies have conducted more than 8,200 clinical trials of new medicines in Texas over the last 13 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). The report – “Research in Your Backyard: Pharmaceutical Clinical Trials in Texas” – was released today at a news conference with Sen. Bob Deuell, (R - Greenville), Rep. Jim Murphy, (R - Houston), Tom Kowalski, President, Texas Healthcare and Bioscience Institute and Dr. Curtis Triplitt, Asst. Professor, Diabetes/Medicine, the University of Texas Health Science Center at San Antonio Texas Diabetes Institute, in the Lt. Governor's Press Conference Room at the State Capitol.
More
More Than 400 Innovative Medicines in Development For Top Chronic Diseases Affecting Older Americans
3/20/2013
Two Reports Show Progress in Treatment Options for Chronic Disease
WASHINGTON, D.C. (March 20, 2013) – America’s biopharmaceutical research companies are developing 465 new medicines that target the 10 leading chronic conditions affecting seniors, according to a new report and overview released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
More
Biologics Research Promises to Bolster Future of Medicine
3/11/2013
More Than 900 Biologic Medicines and Vaccines in Development
WASHINGTON, D.C. (March 11, 2013) – America’s biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
More
PhRMA Urges Trans-Pacific Partnership Negotiators to Adopt a Strong Intellectual Property Framework
3/4/2013
IP Protections Critical to Development of New, Life-Saving Medicines
SINGAPORE (March 4, 2013) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today called on nations participating in the 16th round of Trans-Pacific Partnership (TPP) negotiations to prioritize the protection of intellectual property, citing the critical importance of strong IP to develop innovative treatments for diseases ranging from Alzheimer’s and Parkinson’s to cancer and diabetes. Additionally, as multiple studies have proven over time, IP is the lifeblood of innovation and directly contributes to job creation, worldwide economic growth and patient access to medicine.
More

Subscribe to our Email Updates